Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2014-02-14 Major Shareholding Noti…
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
SC 13D/A
Major Shareholding Notification
2014-02-14 English
SC 13G/A
Major Shareholding Notification
2014-02-12 English
IRANNOTICE
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the US Securities and Exchange Commission referencing a disclosure filed in the company's Annual Report on Form 20-F for the year ended December 31, 2013. It specifically mentions compliance with the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act. The document itself is a notice of disclosure related to the Annual Report but does not contain the Annual Report or substantive financial data. The document length is short (1144 characters), and it serves as a notification about the filing rather than the report itself. According to the 'Menu vs Meal' rule, this is an announcement or notice about a report, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for such regulatory notices and compliance documents.
2014-01-29 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It references exhibits including a Financial Report for Q4 2013 and an Interim Financial Report, but the document itself is a submission notice and does not contain the full financial data or detailed report content. The document length is short (1497 characters), and it primarily serves as a regulatory filing to report the submission of other reports. According to the rules, such filings that do not contain the full report but announce or submit it should be classified as Regulatory Filings (RNS).
2014-01-29 English
20-F
Annual Report FY 2013
2014-01-29 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is a media release announcing Novartis's plan to request re-examination of a drug (serelaxin) for conditional marketing authorization in the EU, including clinical trial updates and regulatory status. It is not a full financial report, audit report, or earnings release. It is a regulatory announcement providing material information to investors and the SEC but does not contain financial statements or detailed financial analysis. The document length is 14,624 characters, which is substantial but the content is primarily a press release and regulatory update. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2014-01-24 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.